Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Current Assets: 2010-2025

Historic Current Assets for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to $229.4 million.

  • Heron Therapeutics' Current Assets rose 17.53% to $229.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $229.4 million, marking a year-over-year increase of 17.53%. This contributed to the annual value of $209.0 million for FY2024, which is 10.72% up from last year.
  • Heron Therapeutics' Current Assets amounted to $229.4 million in Q3 2025, which was up 8.76% from $210.9 million recorded in Q2 2025.
  • Heron Therapeutics' Current Assets' 5-year high stood at $366.8 million during Q2 2021, with a 5-year trough of $165.3 million in Q2 2023.
  • For the 3-year period, Heron Therapeutics' Current Assets averaged around $196.4 million, with its median value being $194.0 million (2023).
  • Per our database at Business Quant, Heron Therapeutics' Current Assets plummeted by 47.06% in 2022 and then climbed by 17.53% in 2025.
  • Heron Therapeutics' Current Assets (Quarterly) stood at $254.4 million in 2021, then fell by 19.25% to $205.4 million in 2022, then decreased by 8.11% to $188.8 million in 2023, then increased by 10.72% to $209.0 million in 2024, then rose by 17.53% to $229.4 million in 2025.
  • Its Current Assets was $229.4 million in Q3 2025, compared to $210.9 million in Q2 2025 and $212.8 million in Q1 2025.